Trevi Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
TRVI$14.91-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(36,496) | $(21,244) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 2,671 | 1,713 |
| Operating lease right-of-use assets | 262 | 259 |
| Depreciation and amortization | 109 | 88 |
| Accretion of available-for-sale marketable securities, net | (1,070) | (1,774) |
| Accretion/accrual of term loan discounts and debt issuance costs | — | 180 |
| Loss on disposal of property, equipment and leasehold improvements | — | 10 |
| Changes in operating assets and liabilities: | ||
| Accrued expenses and other liabilities | 3,276 | 28 |
| Prepaid expenses and other current assets | 2,736 | (2,935) |
| Accounts payable | (194) | (1,676) |
| Net cash used in operating activities | (28,706) | (25,351) |
| Investing activities: | ||
| Proceeds from maturities of available-for-sale marketable securities | 55,643 | 55,679 |
| Purchases of available-for-sale marketable securities | (53,271) | (8,981) |
| Purchases of property, equipment and leasehold improvements | (28) | (115) |
| Net cash provided by investing activities | 2,344 | 46,583 |
| Financing activities: | ||
| Proceeds from at-the-market sales, net of commissions | 9,697 | 1,710 |
| Proceeds from exercises of stock options | 381 | 73 |
| Proceeds from employee stock purchase plan | 34 | 33 |
| Payments of finance lease | (95) | (63) |
| Repayments of term loan | — | (9,409) |
| Payments of offering costs | — | (200) |
| Net cash provided by (used in) financing activities | 10,017 | (7,856) |
| Net (decrease) increase in cash and cash equivalents | (16,345) | 13,376 |
| Cash and cash equivalents at beginning of period | 32,397 | 12,589 |
| Cash and cash equivalents at end of period | $16,052 | $25,965 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.